BioCentury | May 31, 2010
Finance

Performance Counts

...HCV, follicular lymphoma:; IPH 2101 - multiple myeloma] Biology: lymphocyte biology Micromet Inc. (NASDAQ:MITI) (formerly Micromet AG...
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

...with cash and had three analysts covering them. That would have been the best move." Micromet AG...
BioCentury | May 15, 2006
Company News

CancerVax, Micromet AG deal

...Micromet Inc. and trades on NASDAQ under the symbol MITI. CancerVax Corp. (CNVX), Carlsbad, Calif. Micromet AG...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...Europe can develop the same professional networks soon," he said. Following suit have been Germany’s Micromet AG...
BioCentury | Apr 10, 2006
Clinical News

Micromet AG preclinical data

...growing in mice. MT110 is a bispecific T cell engager (BiTE) targeting the Ep-CAM antigen. Micromet AG...
BioCentury | Mar 6, 2006
Tools & Techniques

Dosing anticancer antibodies

...trying to improve the efficacy in order to lower the required doses, research done by Micromet AG...
BioCentury | Feb 27, 2006
Tools & Techniques

Kiss of death

...Compounds based on Micromet AG 's bispecific T cell engagers technology have been in the clinic for...
BioCentury | Feb 27, 2006
Strategy

The sum greater than the whole

...several opportunities," CEO Gregor Cevc told BioCentury. One possibility was to follow the route of Micromet AG...
BioCentury | Jan 30, 2006
Strategy

The inside story

...which were deals with CancerVax Corp. (CNVX, Carlsbad, Calif.), ZymoGenetics Inc. (ZGEN, Seattle, Wash.) and Micromet AG...
BioCentury | Jan 23, 2006
Company News

Micromet AG, Abbott, Alligator Bioscience, Haptogen deal

...linkers and protein fusion technology with ENZN's patents covering SCAs (see BioCentury, April 15, 2002). Micromet AG...
Items per page:
1 - 10 of 55
BioCentury | May 31, 2010
Finance

Performance Counts

...HCV, follicular lymphoma:; IPH 2101 - multiple myeloma] Biology: lymphocyte biology Micromet Inc. (NASDAQ:MITI) (formerly Micromet AG...
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

...with cash and had three analysts covering them. That would have been the best move." Micromet AG...
BioCentury | May 15, 2006
Company News

CancerVax, Micromet AG deal

...Micromet Inc. and trades on NASDAQ under the symbol MITI. CancerVax Corp. (CNVX), Carlsbad, Calif. Micromet AG...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...Europe can develop the same professional networks soon," he said. Following suit have been Germany’s Micromet AG...
BioCentury | Apr 10, 2006
Clinical News

Micromet AG preclinical data

...growing in mice. MT110 is a bispecific T cell engager (BiTE) targeting the Ep-CAM antigen. Micromet AG...
BioCentury | Mar 6, 2006
Tools & Techniques

Dosing anticancer antibodies

...trying to improve the efficacy in order to lower the required doses, research done by Micromet AG...
BioCentury | Feb 27, 2006
Tools & Techniques

Kiss of death

...Compounds based on Micromet AG 's bispecific T cell engagers technology have been in the clinic for...
BioCentury | Feb 27, 2006
Strategy

The sum greater than the whole

...several opportunities," CEO Gregor Cevc told BioCentury. One possibility was to follow the route of Micromet AG...
BioCentury | Jan 30, 2006
Strategy

The inside story

...which were deals with CancerVax Corp. (CNVX, Carlsbad, Calif.), ZymoGenetics Inc. (ZGEN, Seattle, Wash.) and Micromet AG...
BioCentury | Jan 23, 2006
Company News

Micromet AG, Abbott, Alligator Bioscience, Haptogen deal

...linkers and protein fusion technology with ENZN's patents covering SCAs (see BioCentury, April 15, 2002). Micromet AG...
Items per page:
1 - 10 of 55